Johnson & Johnson plans to spend more than $55 billion to build four plants in the U.S. over the next four years, it said on ...

Johnson & Johnson has laid out plans to raise U.S. investments by 25% to more than $55 billion over the next four years, as a ...

How GLP-1 drugs, regulatory concerns, and more factors are shaping the sector. Plus, 3 undervalued healthcare stocks.

Johnson & Johnson plans to spend more than US$55 billion to build plants in the U.S. over the next four years, after the ...

Following big announcements from Lilly and Merck, J&J is pledging $55 billion over the next four years to open new plants.

Alnylam's Amvuttra enters ATTR-CM drug race, and Expedition Therapeutics seeks to bring Chinese drugs to the U.S.

The alert describes a problem that can lead to excessive pressure in the kidney during procedures to remove urinary stones.

Big raises slowed for the second week in a row. Only a handful of rounds hit nine digits this week, although a large ...

Automated three-dimensional total-body photography improves the efficiency of positive malignant biopsies and reduces ...

The FDA has issued an early alert regarding a potential safety issue with Calyxo’s CVAC Aspiration System, warning that improper use can lead to serious injury or death. On Feb. 19, Calyxo notified ...